WO2004009622A3 - Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies - Google Patents

Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies Download PDF

Info

Publication number
WO2004009622A3
WO2004009622A3 PCT/EP2003/007835 EP0307835W WO2004009622A3 WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3 EP 0307835 W EP0307835 W EP 0307835W WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
cancer
development
diseases
protein complexes
Prior art date
Application number
PCT/EP2003/007835
Other languages
English (en)
Other versions
WO2004009622A2 (fr
Inventor
Alejandro Merino
Tewis Bouwmeester
Andreas Bauer
Gerard Drewes
Martina Marzioch
Ulrich Kruse
Giulio Superti-Furga
Dirk Eberhard
Heinz Ruffner
Scott Hobson
Gerd Helftenbein
Cristina Cruciat
Original Assignee
Cellzome Ag
Alejandro Merino
Tewis Bouwmeester
Andreas Bauer
Gerard Drewes
Martina Marzioch
Ulrich Kruse
Giulio Superti-Furga
Dirk Eberhard
Heinz Ruffner
Scott Hobson
Gerd Helftenbein
Cristina Cruciat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag, Alejandro Merino, Tewis Bouwmeester, Andreas Bauer, Gerard Drewes, Martina Marzioch, Ulrich Kruse, Giulio Superti-Furga, Dirk Eberhard, Heinz Ruffner, Scott Hobson, Gerd Helftenbein, Cristina Cruciat filed Critical Cellzome Ag
Priority to AU2003281515A priority Critical patent/AU2003281515A1/en
Publication of WO2004009622A2 publication Critical patent/WO2004009622A2/fr
Publication of WO2004009622A3 publication Critical patent/WO2004009622A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des complexes protéiniques qui entrent en jeu dans des processus cellulaires qui se sont avérés critiques pour le développement de diverses formes de cancer, des protéines composant de ces complexes, des fragments et des dérivés de ces protéines composant et, des anticorps spécifiques de ces complexes. Cette invention concerne aussi des techniques d'utilisation de ces complexes et leur protéines d'interaction dans la recherche, le diagnostic et la thérapie, entre autres domaines d'utilisation, ainsi que des techniques de préparation de ces complexes.
PCT/EP2003/007835 2002-07-19 2003-07-18 Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies WO2004009622A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003281515A AU2003281515A1 (en) 2002-07-19 2003-07-18 Protein complexes of cellular networks underlying the development of cancer and other diseases

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP02016109 2002-07-19
EP02016123.8 2002-07-19
EP02016128 2002-07-19
EP02016109.7 2002-07-19
EP02016111.3 2002-07-19
EP02016111 2002-07-19
EP02016123 2002-07-19
EP02016128.7 2002-07-19
EP02016427.3 2002-07-22
EP02016427 2002-07-22

Publications (2)

Publication Number Publication Date
WO2004009622A2 WO2004009622A2 (fr) 2004-01-29
WO2004009622A3 true WO2004009622A3 (fr) 2004-09-10

Family

ID=30773697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007835 WO2004009622A2 (fr) 2002-07-19 2003-07-18 Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies

Country Status (2)

Country Link
AU (1) AU2003281515A1 (fr)
WO (1) WO2004009622A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US12121590B2 (en) 2023-06-06 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
CA2522700A1 (fr) * 2003-04-18 2004-11-04 Cytovia, Inc. Procedes pour traiter des maladies entrainant l'induction d'apoptose et essais de criblage
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US10337054B2 (en) 2004-02-02 2019-07-02 Quantum-Si Incorporated Enrichment of nucleic acid targets
EP2286844A3 (fr) 2004-06-01 2012-08-22 Genentech, Inc. Conjugués anticorps-médicament et procédés
WO2005124360A2 (fr) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Utilisation d'une proteine tebp en tant que marqueur pour le cancer du sein
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2007035494A2 (fr) * 2005-09-16 2007-03-29 The Regents Of The University Of California Induction de l'expression de puma permettant de reduire l'inflammation articulaire dans le traitement de l'arthrite
AU2007221234A1 (en) * 2006-02-24 2007-09-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
WO2008104805A2 (fr) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
EP2579897A1 (fr) 2010-06-08 2013-04-17 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
WO2012038744A2 (fr) * 2010-09-22 2012-03-29 Genome Research Limited Détection de mutations
EP2640727B1 (fr) 2010-11-17 2015-05-13 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
SI2906251T1 (en) 2012-10-12 2018-01-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
SI2906298T1 (sl) 2012-10-12 2018-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
KR101986404B1 (ko) 2012-10-12 2019-06-07 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015052532A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépines
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112016013861A2 (pt) 2013-12-16 2017-10-10 Genentech Inc conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック, インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composes d'amine quaternaire et conjugues anticorps-medicament de ceux-ci
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US11130986B2 (en) * 2015-05-20 2021-09-28 Quantum-Si Incorporated Method for isolating target nucleic acid using heteroduplex binding proteins
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
EP3465221B1 (fr) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック, インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
EP3299456A1 (fr) * 2016-09-26 2018-03-28 Université de Strasbourg Gène dgkk recombinant pour thérapie génique du syndrome x-fragile
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3047683C (fr) 2017-02-08 2020-03-10 Adc Therapeutics Sa Conjugues anticorps-pyrrolobenzodiazepine
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
LT3612537T (lt) 2017-04-18 2022-10-10 Medimmune Limited Pirolobenzodiazepino konjugatai
BR112019021880A2 (pt) 2017-04-20 2020-06-02 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo anti-axl-droga
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
LT3668874T (lt) 2017-08-18 2022-03-25 Medimmune Limited Pirolobenzodiazepino konjugatai
RU2020113749A (ru) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. Аналоги таиланстатина
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2020219504A1 (fr) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulation de la survie de cellules thérapeutiques et procédés, cellules et acides nucléiques associés à celles-ci
CA3159566A1 (fr) 2019-10-29 2021-05-06 Quantum-Si Incorporated Pompage peristaltique de fluides et procedes, systemes et dispositifs associes
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2002092626A2 (fr) * 2001-05-15 2002-11-21 Cellzome Ag Complexe de polyadenylation et de clivage et arnm precurseur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2002092626A2 (fr) * 2001-05-15 2002-11-21 Cellzome Ag Complexe de polyadenylation et de clivage et arnm precurseur

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAUMANN PETER ET AL: "Pot1, the putative telomere end-binding protein in fission yeast and humans", SCIENCE (WASHINGTON D C), vol. 292, no. 5519, 11 May 2001 (2001-05-11), pages 1171 - 1175, XP002261020, ISSN: 0036-8075 *
BLACKBURN ELIZABETH H: "Switching and signaling at the telomere", CELL, vol. 106, no. 6, 21 September 2001 (2001-09-21), pages 661 - 673, XP002261021, ISSN: 0092-8674 *
GAVIN A-C ET AL: "Functional organization of the yeast proteome by systematic analysis of protein complexes", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, January 2002 (2002-01-01), pages 141 - 147, XP002958851, ISSN: 0028-0836 *
HO Y ET AL: "Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, 10 January 2002 (2002-01-10), pages 180 - 183, XP002250082, ISSN: 0028-0836 *
KUMAR ANUJ ET AL: "Protein complexes take the bait.", NATURE. ENGLAND 10 JAN 2002, vol. 415, no. 6868, 10 January 2002 (2002-01-10), pages 123 - 124, XP002261019, ISSN: 0028-0836 *
PAWSON^A^ ^B T ET AL: "Interaction domains: from simple binding events to complex cellular behavior", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 513, no. 1, 20 February 2002 (2002-02-20), pages 2 - 10, XP004344928, ISSN: 0014-5793 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US12121590B2 (en) 2023-06-06 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
WO2004009622A2 (fr) 2004-01-29
AU2003281515A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
WO2004013180A3 (fr) Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
WO2004029093A3 (fr) Anticorps anti-granulocytes chimeres, humains et humainises
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
WO2004058171A3 (fr) Anticorps anti-gpr64 et utilisations
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
WO2007067991A3 (fr) Anticorps monoclonaux humains se fixant a l'o8e
WO2006068975A3 (fr) Proteines de liaison specifiques de la matriptase humaine
WO2007005874A3 (fr) Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
WO2005000901A3 (fr) Anticorps specifiques de cd20 et leurs methodes d'utilisation
WO2007092640A3 (fr) Anticorps qui se lient à par-2
WO2004092215A3 (fr) Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine
WO2005003298A3 (fr) Resultat de l'utilisation d'agents therapeutiques succedanes dans l'immunotherapie a base d'anti-ctla-4
WO2003076592A3 (fr) Nouvelle methode d'administration et de synthese intracellulaire de molecules sirna
WO2003099205A3 (fr) Traitement du carcinome renal a l'aide d'anticorps diriges contre le recepteur du facteur de croissance epidermique
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
WO2004094473A3 (fr) Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2004094476A3 (fr) Compositions et methodes se rapportant a stop-1
WO2004069860A3 (fr) Proteines conjuguees a isg15
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP